Trial Profile

A Phase I Study of TQB3455 Tablets in Subjects With Advanced Malignancies

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 11 Jan 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs TQB 3455 (Primary)
Indications Acute myeloid leukaemia; Myelodysplastic syndromes; Solid tumours
Focus Adverse reactions
Sponsors Chia Tai Tianqing Pharmaceutical Group

Most Recent Events

13 Dec 2022 Results assessing safety and clinical efficacy of TQB3455 monotherapy in pts with mIDH2-positive AML or MDS presented at the 64th American Society of Hematology Annual Meeting and Exposition
30 Jun 2020 Status changed from not yet recruiting to recruiting.
14 Apr 2020 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com